Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia

Figures & data

Table 1. Patients’ characteristics

Age [year], median [range]	46 (13–79)
gender [female/male]	1∶1·2
FAB subtype [n]
M0	9
M1	31
M2	12
M3	2
M4	9
M5	6
M6	4
Cytogenetic risk [n]
Favorable prognosis	4
Intermediate prognosis	26
Poor prognosis	5
Not determined	43
AML p/s [n]
Primary	65
Secondary	13

Figure 1. Mononuclear PB cells from AML patients were analyzed by FACS analysis using fluorochrome labeled anti-FR/FL and TR1/TR2 antibodies. Percentages of myeloid cells and T cells for the respective FR, FL and TR1, TR2 co-expressions are presented on MNCs from AML patients at first diagnosis compared to healthy probands. (A) Co-expression of FasR or FasL and TrailR1 or TrailR2 on myeloid cells. (B) Co-expression of FasR or FasL and TrailR1 or TrailR2 on T cells.

Figure 2. Mononuclear PB cells from AML patients were analyzed by FACS analysis using fluorochrome labeled anti-FR/FL and TR1/TR2 antibodies. Percentages of myeloid cells and T cells for the respective FR, FL and TR1, TR2 co-expressions are presented on MNCs from AML patients in different stages of AML. (A) Percentages of myeloid cells and T cells for the respective FR, FL and TR1, TR2 co-expressions are presented on MNCs from AML patients in pAML compared to sAML. (B) Percentages of myeloid cells and T cells for the respective FR, FL and TR1, TR2 co-expressions are presented on MNCs from AML patients in favorable vs poor cytogenetic risk group. (C) Percentages of myeloid cells and T cells for the respective FR, FL and TR1, TR2 co-expressions are presented on MNCs from AML patients in the responder compared to the non-responder-group to chemotherapy.

Figure 3. Mononuclear PB cells from AML patients were analyzed by FACS analysis using fluorochrome labeled anti-FR/FL and TR1/TR2 antibodies and percentages of myeloid cells and T cells co-expressing the respective FR, FL and TR1, TR2 markers evaluated. Cases were separated each in two prognostic groups after evaluating a cut-off value representing the value of maximum probability with a most significant differentiation between cases with a shorter or longer overall survival. Kaplan–Meier plots and the respective P values by log-rank test for TR1/CD33 and TR1/CD3 co-expressions are given.